vidarabine has been researched along with Leukemia in 119 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (14.29) | 18.7374 |
| 1990's | 26 (21.85) | 18.2507 |
| 2000's | 48 (40.34) | 29.6817 |
| 2010's | 24 (20.17) | 24.3611 |
| 2020's | 4 (3.36) | 2.80 |
| Authors | Studies |
|---|---|
| Arpinati, M; Baronciani, D; Bernasconi, P; Bonifazi, F; Brunello, L; Bruno, B; Busca, A; Carella, AM; Carluccio, P; Casini, M; Chiusolo, P; Ciceri, F; Cilloni, D; Cupri, A; Di Grazia, C; Gheorghiu, A; Giglio, F; Girmenia, C; Grassi, A; Grillo, G; Iori, AP; Luppi, M; Martino, M; Masciulli, A; Musso, M; Nozzoli, C; Oldani, E; Onida, F; Palazzo, G; Parma, M; Patriarca, F; Pavoni, C; Peccatori, J; Picardi, A; Proia, A; Rambaldi, A; Sacchi, N; Santarone, S; Sorasio, R; Tringali, S; Vacca, A; Vallisa, D | 1 |
| Beutel, G; Dammann, E; Eder, M; Eggers, H; Ehrlich, S; Gabdoulline, R; Ganser, A; Göhring, G; Hambach, L; Heuser, M; Klement, P; Koenecke, C; Markel, D; Neziri, B; Rehberg, A; Reuter, M; Schlegelberger, B; Shahswar, R; Stadler, M; Thol, F; Wichmann, M | 1 |
| Kolb, HJ; Schmid, C | 1 |
| Chaudhury, S; Duerst, RE; Jacobsohn, D; Kletzel, M; Kwon, S; Rossoff, J; Schneiderman, J; Tse, WT | 1 |
| Chan, KW; De Oliveira, S; Eapen, M; Fei, M; Hattersely, G; Horowitz, MM; Kurtzberg, J; Mendizabal, A; Schultz, KR; Wagner, JE; Wall, D; Zhang, MJ | 1 |
| Farooq, A; Farooq, MU; Khan, DH; Mir, MA; Mushtaq, F | 1 |
| Alloush, H; Anderson, E; Conway, M; Lamont, J; Martin, A; Mehta, P; Ruddock, M; Salisbury, V; Smith, JG; Smith, MA | 1 |
| Arakawa, T; Hino, M; Koh, H; Nakamae, H; Nakane, T; Nishimoto, M; Ohsawa, M; Watanabe, K | 1 |
| Hirabayashi, K; Koike, K; Kurata, T; Nakazawa, Y; Saito, S; Sakashita, K; Tanaka, M; Yanagisawa, R; Yoshikawa, K | 1 |
| Alberti, N; Crombe, A; De Roquefeuil, E; Dousset, V; Gilles, M; Guy, A; Tourdias, T | 1 |
| Barba, P; Bautista, G; Cabrera, JR; Duarte, R; Esquirol, A; Fores, R; García, I; García-Marco, JA; Heras, I; Marquez-Malaver, FJ; Martino, R; Parody, R; Regidor, C; Rovira, M; Saavedra, S; Sánchez-Ortega, I; Serrano, D; Sierra, J; Vazquez, L | 1 |
| Boztug, H; Cant, A; Glogova, E; Lankester, A; Peters, C; Pötschger, U; Skinner, R; Slatter, M; Sykora, KW; Veys, P; Wachowiak, J; Zecca, M | 1 |
| Deng, L; Huang, QX; Huang, R; Huang, YX; Li, YH; Song, CY; Tu, SF; Wu, BY | 1 |
| Gao, ZY; Li, WD; Lu, DP; Lu, DY; Yu, XJ | 1 |
| Hawkes, N | 1 |
| Ikegame, K; Inoue, T; Ishii, S; Kaida, K; Kojima, H; Kusunoki, Y; Ogawa, H; Okada, M; Saji, H; Soma, T; Tamaki, H; Yoshihara, K; Yoshihara, S | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Christopherson, RI; Crossett, B; Gez, S; Henrich, S; Mulligan, SP | 1 |
| Mattsson, J; Remberger, M; Ringdén, O; Svahn, BM | 1 |
| Almenara, JA; Atadja, P; Coe, S; Dent, P; Grant, S; Maggio, SC; Rosato, RR | 1 |
| Kamijo, T; Koike, K; Nakazawa, Y; Sakashita, K; Shikama, N; Shiohara, M; Tanaka, M; Yanagisawa, R | 1 |
| Hong, M; Li, JY; Qian, SX; Qiu, HX; Wu, HX; Xu, W; Zhang, R | 1 |
| Horiike, S; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Ohshiro, M; Sasaki, N; Shimazaki, C; Shimura, Y; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Yamamoto, M | 1 |
| Alyea, E; Antin, JH; Armand, P; Attar, E; Ballen, K; Boussiotis, VA; Brown, J; Cutler, C; Dey, BR; Herrera, M; Ho, V; Kao, G; Kim, HT; Koreth, J; Liney, D; McDonough, S; Reynolds, C; Ritz, J; Soiffer, R; Spitzer, T; Stevenson, K | 1 |
| Cai, YX; Lu, QY; Niu, XQ; Wang, Z; Zaho, JN | 1 |
| Allen, JC; Chowbay, B; Diong, CP; Goh, YT; Hwang, WY; Linn, YC; Loh, SM; Wong, AM | 1 |
| Chen, S; Du, X; Li, Y; Liu, Q; Wu, J; Wu, X; Yang, L; Zhu, K | 1 |
| Hwang, HJ; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Seol, M; Shin, HJ; Yun, SC | 1 |
| Iwasaki, H; Kawai, Y; Takagi, K; Ueda, T; Yamauchi, T | 1 |
| Busemann, C; Dölken, G; Kiefer, T; Krüger, WH; Neumann, T; Wilfert, H | 1 |
| Dai, Y; Dent, P; Grant, S; Hock, S; Rosato, R | 1 |
| Liu, X; Wan, Q; Xi, A; Zhang, C | 1 |
| Bae, SH; Hyun, MS; Joo, YD; Kim, DY; Kim, H; Kim, MK; Kim, SD; Lee, GW; Lee, JH; Lee, KH; Lee, WS; Min, YJ; Park, JH; Ryoo, HM | 1 |
| Ayari, S; Blin, N; Chevallier, P; Clavert, A; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Le Bourgeois, A; Le Gouill, S; Lestang, E; Mahe, B; Mohty, M; Moreau, P; Planche, L; Roland, V; Tessoulin, B | 1 |
| Guo, K; Song, Z; Wu, B; Xiao, L; Yan, D; Yang, Y | 1 |
| Balcerzak, SP; Bloomfield, CD; Byrd, JC; Caligiuri, MA; Cataland, SR; Chan, KK; Dai, G; Farag, SF; Fisher, DB; Frankel, SR; Grever, MR; Klisovic, MI; Kourlas, PJ; Kraut, EH; Lin, ZP; Lucas, D; Marcucci, G; Porcu, P; Young, DC; Zwiebel, JA | 1 |
| Basara, N; Fauser, AA; Guenzelmann, S; Kiehl, MG; Kraut, L; Roemer, E; Schmetzer, B | 1 |
| Aversa, F; Carotti, A; Falcinelli, F; Felicini, R; Martelli, MF; Tabilio, A; Terenzi, A; Velardi, A | 1 |
| Albertioni, F; Elford, H; Eriksson, S; Flordal, E; Lagercrantz, S; Liliemark, J; Månsson, E; Spasokoukotskaja, T | 1 |
| Agura, E; Anasetti, C; Blume, K; Chauncey, T; Hegenbart, U; Heimfeld, S; Maloney, D; Maris, MB; McSweeney, P; Niederwieser, D; Petersdorf, E; Pulsipher, M; Sandmaier, BM; Slattery, J; Storb, R; Storer, B; Stuart, M; Woolfrey, A | 1 |
| Fruchtman, S; Grosskreutz, C; Isola, L; Ross, V; Scigliano, E | 1 |
| Huang, XJ; Lu, DP; Lu, J | 1 |
| Casper, J; Dölken, G; Freund, M; Hammer, U; Hartung, G; Kiefer, T; Kleine, HD; Knauf, W; Knopp, A; Steiner, B; Wegener, R; Wilhelm, S; Wolff, D | 1 |
| Fujioka, T; Ikegame, K; Kawakami, M; Kawase, I; Ogawa, H; Oji, Y; Oka, Y; Sugiyama, H; Tamaki, H; Tsuboi, A | 1 |
| Ueda, T; Yamauchi, T | 1 |
| Aschan, J; Blau, I; Casper, J; Doelken, G; Freund, M; Giebel, S; Holowiecki, J; Knauf, W; Kroger, N; Ruutu, T; Schafer-Eckart, K; Volin, L; Wandt, H; Zander, A | 1 |
| Acharya, MR; Figg, WD | 1 |
| Grigg, AP; Januszewicz, EH; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM | 1 |
| Burnett, AK; Milligan, DW; Wheatley, K | 1 |
| Lamanna, N; Weiss, M | 1 |
| Baron, F; Chauncey, TR; Diaconescu, R; Flowers, ME; Maloney, DG; Maris, MB; Mielcarek, M; Sandmaier, BM; Sorror, M; Storb, R; Storer, BE; Woolfrey, AE | 1 |
| Li, WX; Mao, X; Yu, C | 1 |
| Kalhorn, TF; McCune, JS; Ren, AG; Slattery, JT; Wang, J | 1 |
| Blumstein, N; Buchmann, I; Buck, AK; Bunjes, D; Döhner, H; Glatting, G; Kotzerke, J; Neumaier, B; Reske, SN; Ringhoffer, M; Schauwecker, P; Stilgenbauer, S; von Harsdorf, S; Wiesneth, M; Zenz, T | 1 |
| Bowcock, SJ; Lim, Z; Mufti, GJ; Rassam, SM; Ryali, MM; Ward, SM | 1 |
| Croce, C | 1 |
| Chen, J; Li, JP; Zhang, T; Zhong, J; Zhu, KE | 1 |
| Alimoghaddam, K; Ashouri, A; Chahardovali, B; Evazi, MR; Ghaffari, SH; Ghavamzadeh, A; Iravani, M; Mousavi, SA; Samiee, S; Shamshiri, AR; Tavakoli, M | 1 |
| Chae, YS; Cho, GJ; Cho, YY; Chung, JS; Kim, HJ; Kim, JG; Kim, YK; Lee, JJ; Moon, JH; Shin, HJ; Sohn, SK; Yang, DH | 1 |
| Hardan, I; Herscovici, C; Nagler, A; Rand, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R | 1 |
| Esser, R; Kalaäoui, RE; Klingebiel, T; Kloess, S; Koehl, U; Kreuter, J; Lehrnbecher, T; Munkelt, D; Schubert, R; Schwabe, D; Wehner, S; Zimmermann, SY | 1 |
| Beri, R; Chen, YH; Chunduri, S; Dobogai, LC; Hurter, E; Mahmud, N; Peace, D; Quigley, J; Rondelli, D; Saunthararajah, Y | 1 |
| Auberger, J; Clausen, J; Erdel, M; Gastl, G; Gunsilius, E; Nachbaur, D; Petzer, A; Willenbacher, W | 1 |
| Hirsch, MS; Wong, KK | 1 |
| Bakay, B; Bleeker, LC; Kung, FH; Matsumoto, SS; Nyhan, WL; Yu, AL | 1 |
| Benjamin, RS; Feun, LG; Freirich, EJ; Keating, M; Nowak, B; Plunkett, W | 1 |
| Agarwal, RP; Kufe, DW; Major, PP | 1 |
| Alford, CA; Betts, R; Dolin, R; Linnemann, C; Soong, SJ; Whitley, RJ | 1 |
| Gandhi, V; Plunkett, W | 5 |
| Dighiero, G | 1 |
| Estey, E; Gandhi, V; Plunkett, W | 1 |
| Gandhi, V; Huang, P; Plunkett, W | 1 |
| Piro, LD; Saven, A | 1 |
| Cheson, BD | 5 |
| Saven, A | 1 |
| Bosly, A; Brousset, P; Delannoy, A; Pris, J; Riga-Huguet, F; Schlaifer, D | 1 |
| Estey, E; Gandhi, V; Keating, MJ; Plunkett, W | 1 |
| Estey, EH; Gandhi, V; Keating, MJ; Plunkett, W | 1 |
| Faure, P; Madelaine-Chambrin, I; Piquet-Sevrin, V | 1 |
| Ueda, T | 1 |
| Wiley, JS | 1 |
| Huang, P; Iwasaki, H; Keating, MJ; Plunkett, W | 1 |
| Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S | 1 |
| Albertioni, F; Eriksson, S; Hullán, L; Sasvári-Székely, M; Spasokoukotskaja, T; Staub, M | 1 |
| Bosanquet, AG | 1 |
| Bardy, P; Byron, K; Grigg, A; Seymour, JF; Szer, J | 1 |
| Sarper, N; Yalman, N | 1 |
| Catovsky, D; Dearden, CE; Matutes, E | 1 |
| Molinari, A; Poletti, G; Poletti, V; Salvucci, M; Zaccaria, A; Zanchini, R; Zuffa, E | 1 |
| Bishop, MR; McCarthy, NJ | 1 |
| Dai, Y; Decker, R; Dent, P; Grant, S; Harvey, S; Kramer, L; Schaefer, G; Tang, L | 1 |
| Ahlmann, M; Baumann, M; Boos, J; Freund, A; Lanvers, C; Lümkemann, K; Rössig, C | 1 |
| Aker, M; Brautbar, C; Nagler, A; Naparstek, E; Or, R; Slavin, S; Varadi, G | 1 |
| Cantú, OG; Gómez-Almaguer, D; González-Llano, O; Jaime-Pérez, JC; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ | 1 |
| Carbone, GM; Catapano, CV; Fernandes, DJ | 1 |
| Abonour, R; Kim, K; Longo, WL; Mosher, DF; Turman, NJ; Vidarsson, B; Wiersma, SR; Williams, EC; Woodson, RD | 1 |
| Braess, J; Büchner, T; Hiddemann, W; Kern, W; Ohnesorge, J; Schleyer, E; Unterhalt, M; Wittmer, E; Wörmann, B | 1 |
| Craddock, C; Garg, M; Lawler, M; Pawson, R; Potter, MN; Prentice, HG; Rassam, S; Rezvani, K; Theocharous, P; Yin, JA | 1 |
| Dicioccio, RA; Srivastava, BI | 1 |
| Carson, DA; Kaye, J; Seegmiller, JE | 1 |
| Cohen, SS | 1 |
| Bömer, H; Metzger, E; Sauer, O; Schneider, H; Schubert, E; Treuner, J; Werner, GT | 1 |
| Robak, T | 1 |
| Finley, RS; Hood, MA | 1 |
| Fridland, A; Verhoef, V | 1 |
| Hirose, M; Inaba, S; Kuroki, Y; Shimoyama, M | 1 |
| Dandliker, PS; Meyers, JD; Shepp, DH | 1 |
| Huang, P; Plunkett, W | 1 |
| Danhauser, L; Gandhi, V; Iacoboni, S; Keating, M; Liliemark, J; Plunkett, W | 1 |
| Danhauser, L; Gandhi, V; Plunkett, W | 1 |
22 review(s) available for vidarabine and Leukemia
| Article | Year |
|---|---|
The FLAMSA concept-past and future.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Immunotherapy, Adoptive; Leukemia; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2020 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Purine analogs in leukemia.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia; Pentostatin; Purines; Stem Cell Transplantation; Vidarabine | 2004 |
Herpes virus infections in patients with neoplastic disease. Diagnosis and therapy.
Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Bone Marrow Transplantation; Bromodeoxyuridine; Cloning, Molecular; Cytomegalovirus Infections; Herpes Simplex; Herpes Zoster; Herpesviridae Infections; Humans; Infectious Mononucleosis; Interferons; Kidney Transplantation; Leukemia; Lymphopenia; Neoplasms; Pulmonary Fibrosis; Vidarabine | 1984 |
Evolution of the arabinosides and the pharmacology of fludarabine.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cytarabine; Humans; Leukemia; Vidarabine | 1994 |
Potential immunological action of purine nucleoside analogues.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cladribine; Humans; Immunosuppressive Agents; Leukemia; Pentostatin; Purine Nucleosides; Vidarabine | 1994 |
Modulation of arabinosylcytosine metabolism during leukemia therapy.
Topics: Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Biotransformation; Cytarabine; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia; Vidarabine | 1994 |
Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias.
Topics: Acute Disease; Animals; Antineoplastic Agents; DNA Replication; Humans; Leukemia; Leukemia, Experimental; Mice; Vidarabine | 1994 |
The newer purine analogs. Significant therapeutic advance in the management of lymphoid malignancies.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia; Lymphoma; Pentostatin; Vidarabine | 1993 |
Purine analogs in lymphoproliferative disorders.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Multiple Myeloma; Pentostatin; Vidarabine | 1993 |
Comparative efficacy of the newer nucleosides (fludarabine, 2'-deoxycoformycin, and 2-chlorodeoxyadenosine) in the treatment of indolent lymphoid malignancies.
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Humans; Leukemia; Lymphoma; Molecular Structure; Pentostatin; Purine Nucleosides; Vidarabine | 1993 |
Biochemical modulation of arabinosylcytosine for therapy of leukemias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Vidarabine | 1993 |
Intracellular pharmacodynamics in leukemia therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Leukemia; Mitoxantrone; Vidarabine | 1996 |
[Current therapeutic methods in onco-hematology].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cladribine; Docetaxel; Humans; Keratolytic Agents; Leukemia; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Tretinoin; Vidarabine | 1996 |
[Antileukemic agents--new drugs and attempts of rational administration].
Topics: Antineoplastic Agents; Drug Administration Schedule; Humans; Idarubicin; Leukemia; Vidarabine | 1996 |
Perspectives on purine analogues.
Topics: Antineoplastic Agents; Cladribine; Forecasting; Humans; Leukemia; Pentostatin; Purines; Vidarabine | 1996 |
Nonmyeloablative allogeneic stem cell transplantation: early promise and limitations.
Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2000 |
Cellular and clinical pharmacology of fludarabine.
Topics: Antineoplastic Agents; Biological Availability; Deoxycytidine Kinase; DNA (Cytosine-5-)-Methyltransferases; Drug Evaluation, Preclinical; Humans; Leukemia; Lymphoma; Phosphorylation; Vidarabine; Vidarabine Phosphate | 2002 |
The mechanisms of lethal action of arabinosyl cytosine (araC) and arabinosyl adenine (araA).
Topics: Adenine; Adenosine Deaminase Inhibitors; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Azepines; Cell Division; Cell Survival; Cells, Cultured; Cytarabine; Cytidine Deaminase; Cytosine Nucleotides; Deoxyribonucleosides; DNA; Humans; Inosine Nucleotides; Leukemia; Tetrahydrouridine; Vidarabine; Virus Diseases | 1977 |
New antimetabolites in the treatment of human malignancies.
Topics: Animals; Antimetabolites, Antineoplastic; Cladribine; Clinical Trials as Topic; Drugs, Investigational; Forecasting; Humans; Immunosuppression Therapy; Leukemia; Lymphoma; Pentostatin; Purines; Vidarabine | 1992 |
[New analogs of deoxyadenosine for treatment of lymphoid malignancies].
Topics: Antineoplastic Agents; Cladribine; Deoxyadenosines; Formycins; Humans; Leukemia; Lymphoma; Vidarabine | 1992 |
Fludarabine: a review.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Humans; Leukemia; Neoplasms; Remission Induction; Vidarabine | 1991 |
19 trial(s) available for vidarabine and Leukemia
| Article | Year |
|---|---|
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Prospective Studies; Recurrence; Thiotepa; Transplantation Conditioning; Vidarabine | 2022 |
FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia; Male; Middle Aged; Recurrence; Salvage Therapy; Sulfonamides; Vidarabine | 2020 |
Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes.
Topics: Acute Disease; Adolescent; Child; Child, Preschool; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Humans; Infant; Leukemia; Male; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Reduced-toxicity myeloablative conditioning consisting of 8-Gy total body irradiation, cyclophosphamide and fludarabine for pediatric hematological malignancies.
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Female; Gamma Rays; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Male; Myeloablative Agonists; Myelodysplastic Syndromes; Quality of Life; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
[IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 2009 |
[Clinical study of kangai injection plus FLAG regimen for refractory/relapsed acute leukemia].
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drugs, Chinese Herbal; Female; Granulocyte Colony-Stimulating Factor; Humans; Injections; Leukemia; Male; Middle Aged; Vidarabine | 2011 |
Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Female; Gastroenteritis; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Down-Regulation; Female; Genes, bcl-2; Granulocyte Colony-Stimulating Factor; Humans; Leukemia; Male; Middle Aged; Oligonucleotides, Antisense; Remission Induction; Salvage Therapy; Thionucleotides; Vidarabine | 2003 |
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Antigens Class I; Histocompatibility Testing; Humans; Immunosuppressive Agents; Incidence; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Acute; Lymphocyte Transfusion; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Mycophenolic Acid; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Tissue Donors; Vidarabine; Whole-Body Irradiation | 2003 |
Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
Topics: Adult; Aged; Animals; Antilymphocyte Serum; Bone Marrow Diseases; Bone Marrow Transplantation; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Male; Middle Aged; Radiotherapy Dosage; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2003 |
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Busulfan; Chronic Disease; Family; Female; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia; Living Donors; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Lymphoma; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
Topics: Aged; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation; Antilymphocyte Serum; Antineoplastic Agents; Cell Adhesion Molecules; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunosuppressive Agents; Leukemia; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Radioimmunotherapy; Radioisotopes; Radiometry; Rhenium; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2005 |
Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Modulation of arabinosyladenine metabolism by 2'-deoxycoformycin in the therapy of human acute leukemia.
Topics: Adenosine Deaminase; Antineoplastic Agents; Clinical Trials as Topic; Coformycin; Erythrocytes; Humans; Kinetics; Leukemia; Nucleoside Deaminases; Pentostatin; Ribonucleosides; Vidarabine | 1984 |
Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients.
Topics: Adolescent; Adult; Double-Blind Method; Drug Evaluation; Female; Herpes Zoster; Humans; Immunosuppression Therapy; Leukemia; Lymphoma; Male; Middle Aged; Neuralgia; Time Factors; Vidarabine | 1982 |
Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Idarubicin; Infant; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1997 |
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance; Humans; Leukemia; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Therapeutic Equivalency; Treatment Outcome; Vidarabine | 2001 |
Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine.
Topics: Acyclovir; Adolescent; Adult; Child; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Immune Tolerance; Leukemia; Lymphoma; Male; Prospective Studies; Random Allocation; Vidarabine | 1986 |
78 other study(ies) available for vidarabine and Leukemia
| Article | Year |
|---|---|
Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies.
Topics: Antilymphocyte Serum; Busulfan; Child; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Prospective Studies; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2021 |
FLAG vs FLAG-IDA: outcomes in relapsed/refractory acute leukemias.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Middle Aged; Pakistan; Progression-Free Survival; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; Vidarabine; Young Adult | 2019 |
A novel bioluminescent bacterial biosensor for measurement of Ara-CTP and cytarabine potentiation by fludarabine in seven leukaemic cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinofuranosylcytosine Triphosphate; Bacterial Proteins; Biosensing Techniques; Cell Line, Tumor; Cytarabine; HL-60 Cells; Humans; K562 Cells; Leukemia; Luminescent Measurements; Luminescent Proteins; Treatment Outcome; Vidarabine | 2013 |
Successful treatment of both acute leukemia and active Crohn's disease after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and busulfan: a case report.
Topics: Acute Disease; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Crohn Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Transplantation Conditioning; Vidarabine | 2013 |
Extensive acute toxic leukoencephalopathy induced by fludarabine: two months follow-up on brain MRI.
Topics: Antineoplastic Agents; Brain; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging; Follow-Up Studies; Humans; Leukemia; Leukoencephalopathies; Male; Middle Aged; Treatment Outcome; Vidarabine | 2015 |
Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH).
Topics: Adolescent; Adult; Antigens, CD34; Bacterial Infections; Busulfan; Cohort Studies; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Male; Middle Aged; Multivariate Analysis; Mycoses; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Risk Factors; Severity of Illness Index; Thiotepa; Transplantation Conditioning; Vidarabine; Virus Diseases; Whole-Body Irradiation; Young Adult | 2015 |
European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Blood Transfusion; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Europe; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Male; Multivariate Analysis; Retrospective Studies; Societies, Medical; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2016 |
[Clinical Summarization of Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia: A Report of 100 Cases].
Topics: Antilymphocyte Serum; Disease-Free Survival; Graft vs Host Disease; HLA Antigens; Humans; Incidence; Leukemia; Peripheral Blood Stem Cell Transplantation; Recurrence; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2016 |
[Two Kinds of HLA-mismatched Allogeneic Hematopoictic Stem Cell Transplantation for Treatment of Hematologic Malignancies].
Topics: Antilymphocyte Serum; Busulfan; Cyclosporine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Leukemia; Mycophenolic Acid; Stem Cell Transplantation; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
US regulator stops leukemia treatment trial after three patients die.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunotherapy; Leukemia; Treatment Failure; United States; United States Food and Drug Administration; Vidarabine | 2016 |
Spousal hematopoietic stem cell transplantation.
Topics: Adult; Allografts; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fatal Outcome; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Leukemia; Male; Melphalan; Middle Aged; Radiotherapy Dosage; Recurrence; Spouses; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2017 |
Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells.
Topics: Animals; Antibodies; Antigens, CD; Apoptosis; Cattle; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Leukemia; Lymphoma; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Using reduced intensity conditioning and HLA-identical sibling donors, antithymocyte globulin increases the risk of relapse, which can be overcome by a high stem cell dose.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Female; Hematopoietic Stem Cells; HLA Antigens; Humans; Leukemia; Male; Middle Aged; Recurrence; Siblings; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2008 |
Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Caspase 2; Cell Line, Tumor; Cytosol; DNA Damage; DNA Repair; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Leukemia; Reactive Oxygen Species; Superoxide Dismutase; Vidarabine | 2008 |
Low toxicity of a conditioning with 8-Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies.
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Infant; Leukemia; Male; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2009 |
Allogenic bone marrow transplantation with fludarabine/busulfan16 conditioning regimen and dasatinib maintenance therapy for elderly Philadelphia-positive acute/advanced leukemia patients.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Chemotherapy, Adjuvant; Dasatinib; Humans; Immunosuppressive Agents; Leukemia; Male; Philadelphia Chromosome; Pyrimidines; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.
Topics: Adult; Aged; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Melphalan; Middle Aged; Sirolimus; Tacrolimus; Transplantation Conditioning; Vidarabine | 2011 |
[A preliminary study on efficacy of allogeneic hematopoietic stem cell transplantation by myeloablative conditioning regimen with fludarabine for high risk leukemia patients].
Topics: Adolescent; Adult; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2012 |
Frequency analysis of TRBV subfamily sjTRECs to characterize T-cell reconstitution in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Flow Cytometry; Gene Rearrangement, T-Lymphocyte; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Leukemia, Myeloid; Leukocytes, Mononuclear; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Antigen, T-Cell, alpha-beta; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes; Thymus Gland; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Infections; Kaplan-Meier Estimate; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Synergistic effects of combination with fludarabine and carboplatin depend on fludarabine-mediated inhibition of enhanced nucleotide excision repair in leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Humans; K562 Cells; Leukemia; Lymphoma; Salvage Therapy; Vidarabine | 2011 |
Mucositis after reduced intensity conditioning and allogeneic stem cell transplantation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Leukocyte Count; Lymphoma; Male; Methotrexate; Middle Aged; Mucositis; Myelodysplastic Syndromes; Platelet Count; Statistics as Topic; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2011 |
LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Down-Regulation; Drug Synergism; Electrophoretic Mobility Shift Assay; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Humans; Hydroxamic Acids; Indoles; Leukemia; MAP Kinase Kinase 4; Mice; Mice, Nude; NF-kappa B; Panobinostat; Vidarabine; X-Linked Inhibitor of Apoptosis Protein | 2012 |
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunity, Innate; Leukemia; Lymphoma; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Recovery of Function; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
[Application of FBC conditioning regimen in HLA haplotype peripheral blood stem cell transplantation].
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia; Male; Middle Aged; Transplantation Conditioning; Transplantation Tolerance; Vidarabine | 2002 |
Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: a single center experience.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2002 |
Haploidentical stem cell transplantation for acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Disease-Free Survival; Haplotypes; Histocompatibility; Humans; Killer Cells, Natural; Leukemia; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2002 |
Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Cell Line; Cladribine; Clofarabine; Cytogenetics; Deoxycytidine Kinase; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Leukemia; Phenotype; Phosphorylation; Ribonucleotide Reductases; Vidarabine | 2003 |
[The therapeutic effects of FLAG regime for refractory and relapsing acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia; Male; Middle Aged; Recurrence; Vidarabine | 2003 |
Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin.
Topics: Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Leukemia; Male; Middle Aged; Transplantation Conditioning; Vidarabine | 2003 |
Simple and sensitive method for quantification of fludarabine triphosphate intracellular concentration in leukemic cells using isocratic liquid chromatography.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Leukemia; Reproducibility of Results; Sensitivity and Specificity; Vidarabine | 2004 |
Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Cycle Proteins; DNA (Cytosine-5-)-Methyltransferases; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histones; Humans; Leukemia; Pyridines; Reactive Oxygen Species; Vidarabine | 2004 |
A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia; Lymphoma; Male; Middle Aged; Neoplasm Staging; Opportunistic Infections; Risk Factors; Vidarabine | 2004 |
Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Myelodysplastic Syndromes; Vidarabine | 2004 |
Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Comorbidity; Female; Graft Rejection; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Male; Middle Aged; Probability; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2005 |
Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Chromones; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia; MAP Kinase Signaling System; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; U937 Cells; Vidarabine | 2005 |
A highly sensitive high-performance liquid chromatography-mass spectrometry method for quantification of fludarabine triphosphate in leukemic cells.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Jurkat Cells; Leukemia; Mass Spectrometry; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Vidarabine | 2005 |
High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hematologic Neoplasms; Humans; Leukemia; Myelodysplastic Syndromes; Neoplasms, Second Primary; Vidarabine | 2006 |
MicroRNAs in leukemia.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Disease Progression; Flavonoids; Gene Expression Regulation, Leukemic; Humans; Leukemia; Mice; MicroRNAs; Piperidines; Prognosis; Vidarabine | 2006 |
Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
Topics: ABO Blood-Group System; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; beta-Thalassemia; Blood Group Incompatibility; Busulfan; Child, Preschool; Cyclosporine; Epstein-Barr Virus Infections; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Lymphoproliferative Disorders; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Plasma Exchange; Red-Cell Aplasia, Pure; Remission, Spontaneous; Retrospective Studies; Risk Factors; Rituximab; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
Topics: Adolescent; Adult; Busulfan; Child; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia; Male; Middle Aged; Myeloablative Agonists; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Topics: Adolescent; Adult; Arterial Occlusive Diseases; Busulfan; Cyclophosphamide; Cytomegalovirus Infections; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortal
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Busulfan; Caspase 3; Cell Line, Tumor; Child; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Killer Cells, Natural; Leukemia; Stem Cells; T-Lymphocytes; Tetrazolium Salts; Thiazoles; Vidarabine | 2008 |
Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Recurrence; Risk Factors; Survival Rate; Transplantation, Homologous; Vidarabine | 2008 |
Biochemical correlates of the differential sensitivity of subtypes of human leukemia to deoxyadenosine and deoxycoformycin.
Topics: Adenosine Deaminase; Adolescent; Deoxyadenine Nucleotides; Deoxyadenosines; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Lymphocytes; Lymphoma; Male; Nucleotidases; Pentostatin; Thymidine; Vidarabine | 1982 |
Clinical pharmacology of arabinofuranosyladenine in combination with deoxycoformycin.
Topics: Adenosine; Adult; Antineoplastic Agents; Coformycin; Deoxyadenosines; Drug Administration Schedule; Drug Therapy, Combination; Half-Life; Humans; Kinetics; Leukemia; Male; Pentostatin; Ribonucleosides; Vidarabine | 1983 |
Developments in the treatment of leukaemias and lymphomas.
Topics: Animals; Antineoplastic Agents; Humans; Leukemia; Lymphoma; Vidarabine | 1995 |
Secondary neoplasms in two patients treated with purine analogues.
Topics: Acute Disease; Aged; Cladribine; Female; Humans; Immunocompromised Host; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melanoma; Neoplasms, Second Primary; Skin Neoplasms; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Seeking the nucleoside transporter.
Topics: Animals; Antimetabolites, Antineoplastic; Carrier Proteins; Cell Membrane; Cladribine; Cloning, Molecular; Cytarabine; Deoxycytidine; Erythrocytes; Gemcitabine; Glucose Transporter Type 1; Humans; Leukemia; Lymphoma; Membrane Proteins; Monosaccharide Transport Proteins; Nucleosides; Oocytes; Recombinant Proteins; Uridine; Vidarabine; Xenopus | 1997 |
Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.
Topics: Antineoplastic Agents; Binding Sites; Cytarabine; Deoxycytidine; DNA Repair; DNA Replication; DNA, Neoplasm; Gemcitabine; Humans; Leukemia; Tumor Cells, Cultured; Vidarabine | 1997 |
Activation of deoxycytidine kinase by various nucleoside analogues.
Topics: Adenine Nucleotides; Antimetabolites, Antineoplastic; Arabinonucleosides; Cell Cycle; Cells, Cultured; Cladribine; Clofarabine; Cytarabine; Deoxycytidine Kinase; Enzyme Activation; HL-60 Cells; Humans; Leukemia; Lymphocytes; Palatine Tonsil; Thymidine Kinase; Tumor Cells, Cultured; Vidarabine | 1998 |
Re: V.I. Avramis et al., Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a Phase I/II study in pediatric patients with relapsed leukemias. Clin. Can
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Humans; Leukemia; Terminology as Topic; Vidarabine; Vidarabine Phosphate | 1999 |
Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Graft vs Host Disease; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Male; Middle Aged; Stem Cell Transplantation; Stem Cells; Vidarabine | 1999 |
FLAG (fludarabine, high-dose cytarabine and G-CSF) for refractory and high-risk relapsed acute leukemia in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia; Recurrence; Risk Factors; Vidarabine | 2000 |
Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukemia; Leukemia, B-Cell; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Leukemia, T-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Pentostatin; Sezary Syndrome; Survival Rate; Vidarabine | 2000 |
Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone (flan) treatment for acute leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hemorrhage; Humans; Infant, Newborn; Leukemia; Leukemia, Myeloid, Acute; Lung Diseases; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Respiratory Distress Syndrome, Newborn; Staphylococcal Infections; Vidarabine | 2000 |
Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Arabinonucleotides; Blotting, Western; Drug Interactions; Drug Synergism; Enzyme Inhibitors; HL-60 Cells; Humans; Leukemia; Lymphoma; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Staurosporine; U937 Cells; Vidarabine | 2001 |
Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells.
Topics: Adult; Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; HL-60 Cells; Humans; Hydroxyurea; Leukemia; Vidarabine | 2001 |
Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation.
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cell Count; Child; Cohort Studies; Disease-Free Survival; Female; Graft Survival; Histocompatibility; Humans; Leukemia; Life Tables; Lymphoma, Large-Cell, Anaplastic; Male; Middle Aged; Recurrence; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.
Topics: Adolescent; Adult; Ambulatory Care; Busulfan; Child; Cyclophosphamide; Cyclosporine; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Male; Methotrexate; Middle Aged; Neural Tube Defects; Program Evaluation; Recurrence; Survival Analysis; Thalassemia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
Imbalanced DNA synthesis induced by cytosine arabinoside and fludarabine in human leukemia cells.
Topics: Antineoplastic Agents; Cytarabine; DNA Replication; DNA, Neoplasm; Humans; Leukemia; Tumor Cells, Cultured; Vidarabine | 2001 |
Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infections; Infusion Pumps; Leukemia; Lung Diseases; Male; Middle Aged; Nervous System Diseases; Prognosis; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome; Vidarabine | 2001 |
Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Filgrastim; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Recurrence; Reoperation; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Kinetics of inhibition of deoxynucleotide-polymerizing enzyme activities from normal and leukemic human cells by 9-beta-D-arabinofuranosyladenine 5'-triphosphate and 1-beta-D-arabinofuranosylcytosine 5'-triphosphate.
Topics: B-Lymphocytes; Cell Line; Cytarabine; DNA Nucleotidyltransferases; Kinetics; Leukemia; Nucleic Acid Synthesis Inhibitors; T-Lymphocytes; Vidarabine | 1977 |
Metabolism and toxicity of 9-beta-D-arabinofuranosyladenine in human malignant T cells and B cells in tissue culture.
Topics: Adenosine Kinase; B-Lymphocytes; Cell Division; Cell Line; Deoxycytidine; Humans; Kinetics; Leukemia; T-Lymphocytes; Vidarabine | 1979 |
[The virostatic effect of adenine-arabinoside monophosphate. Experimental findings and preliminary clinical experiences].
Topics: Adenosine Monophosphate; Animals; Child; Child, Preschool; Encephalitis; Female; Herpes Simplex; Herpes Zoster; Hodgkin Disease; Humans; Infant; Leukemia; Male; Mice; Rabbits; Solubility; Vaccinia; Vidarabine | 1978 |
The purine analogs--a therapeutic beauty contest.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Deoxyadenosines; Humans; Leukemia; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine | 1992 |
The purine analogs--a therapeutic beauty contest.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Deoxyadenosines; Humans; Leukemia; Pentostatin; Vidarabine | 1992 |
Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides.
Topics: Arabinonucleosides; Arabinonucleotides; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Leukemia; Phosphorylation; Tumor Cells, Cultured; Vidarabine | 1990 |
Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleosides; B-Lymphocytes; Cell Line; Cell Survival; Cytarabine; Deoxyguanosine; Humans; Leukemia; Phosphorylation; T-Lymphocytes; Vidarabine; Vidarabine Phosphate | 1985 |
Interaction of arabinosyl nucleotides in K562 human leukemia cells.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleosides; Arabinonucleotides; Cytarabine; Deoxyribonucleotides; Drug Interactions; Guanosine Triphosphate; Humans; Leukemia; Phosphorylation; Phosphotransferases; Tumor Cells, Cultured; Vidarabine; Vidarabine Phosphate | 1989 |
Potentiation of growth-inhibitory activity of 9-beta-D-arabinofuranosyladenine by 2'-deoxycoformycin in human cultured cell lines derived from leukemias and lymphomas.
Topics: Adenosine Deaminase; Antineoplastic Agents; Cell Division; Coformycin; Drug Stability; Drug Synergism; Humans; Leukemia; Lymphoma; Pentostatin; Ribonucleosides; Tumor Cells, Cultured; Vidarabine | 1989 |
Phosphorolytic cleavage of 2-fluoroadenine from 9-beta-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli. A pathway for 2-fluoro-ATP production.
Topics: Adenine; Adenosine; Adenosine Triphosphate; Animals; Binding, Competitive; Cell Line; Escherichia coli; Humans; Kidney; Kinetics; Leukemia; Liver; Mice; Phosphates; Purine Nucleosides; Rats; Vidarabine | 1987 |
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Humans; Leukemia; Phosphorylation; Tumor Cells, Cultured; Vidarabine | 1988 |
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Topics: Adult; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; DNA Replication; Drug Evaluation; Female; Half-Life; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine | 1987 |
Separation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography.
Topics: Cells, Cultured; Chromatography, High Pressure Liquid; Cytarabine; Humans; Kinetics; Leukemia; Nucleotides; Vidarabine | 1987 |